S3 Ep10: Nick Mitrokostas Discusses New Biosimilar Approval and Outlooks for 2020 - a podcast by Not So Different: a Podcast from The Center for Biosimilars

Recently, Pfizer announced its pegfilgrastim biosimilar (Nyvepria) was approved by the FDA, which marks the first biosimilar approval this year. Although many expected more approvals earlier in the year, experts wonder if the race to find a revolutionary treatment and vaccine for coronavirus disease 2019 (COVID-19) slowed down the approval process and biosimilars have had to take a back seat for the time being.
We sat down with Nick Mitrokostas, an intellectual property lawyer and partner at Goodwin's IP Litigation group, to discuss how this new approval will affect the biosimilar market and what he sees for the rest of 2020.

Further episodes of Not So Different: a Podcast from The Center for Biosimilars

Further podcasts by Not So Different: a Podcast from The Center for Biosimilars

Website of Not So Different: a Podcast from The Center for Biosimilars